Literature DB >> 34274134

Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.

Gerhardt Attard1, Louise C Brown2, Noel W Clarke3, Mahesh K B Parmar2, Nicholas D James4.   

Abstract

Entities:  

Keywords:  Abiraterone acetate; Androgen deprivation therapy; High-risk localised; Prostate cancer

Mesh：

Substances：

Year:  2021        PMID： 34274134     DOI： 10.1016/j.eururo.2021.06.023

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  1 in total

1.  Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Authors:  Gerhardt Attard; Laura Murphy; Noel W Clarke; William Cross; Robert J Jones; Christopher C Parker; Silke Gillessen; Adrian Cook; Chris Brawley; Claire L Amos; Nafisah Atako; Cheryl Pugh; Michelle Buckner; Simon Chowdhury; Zafar Malik; J Martin Russell; Clare Gilson; Hannah Rush; Jo Bowen; Anna Lydon; Ian Pedley; Joe M O'Sullivan; Alison Birtle; Joanna Gale; Narayanan Srihari; Carys Thomas; Jacob Tanguay; John Wagstaff; Prantik Das; Emma Gray; Mymoona Alzoueb; Omi Parikh; Angus Robinson; Isabel Syndikus; James Wylie; Anjali Zarkar; George Thalmann; Johann S de Bono; David P Dearnaley; Malcolm D Mason; Duncan Gilbert; Ruth E Langley; Robin Millman; David Matheson; Matthew R Sydes; Louise C Brown; Mahesh K B Parmar; Nicholas D James
Journal:  Lancet       Date:  2021-12-23       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.